PILOT STUDY FOR IDENTIFYING URINARY PROSTATE CANCER BIOMARKERS

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 尿前列腺癌蛋白生物标志物对于早期癌症检测是重要的。 在这一点上进行尿检可以显着减少由于血清PSA升高而进行的不必要的活检数量。 基因组学在癌细胞中的应用已经允许鉴定许多候选生物标志物以供进一步研究。 这项初步研究将利用先进的靶向蛋白质组学技术，使用资源中心的多反应监测（MRM）来测试尿液样本中已鉴定的癌症蛋白质的区分能力。 预计该应用程序还将推动目标MRM技术的进一步开发和优化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Urinary prostate cancer protein biomarkers are important for early cancer detection. A urine test at this point can significantly reduce the number of unnecessary biopsies done as a result of elevated serum PSA. The application of genomics to cancer cells has allowed the identification of a number of candidate biomarkers for further investigations. This pilot study will utilize the advanced targeted proteomic technology using multiple reaction monitoring (MRM) under the resource center for testing the discriminatory power of identified cancer proteins in urine samples. The application is also anticipated to drive further development and optimization of the targeted MRM technology.